BACKGROUND Although the renin-angiotensin and the beta-adrenergic systems are interrelated, a direct interaction between beta-adrenergic receptors (betaARs) and angiotensin II type 1 receptors (AT1Rs) has not been identified. METHODS AND RESULTS Here, we provide evidence for a functional and physiological interaction between 2 G protein-coupled receptors: the betaAR and the AT1R. Selective bl...

BACKGROUND AND OBJECTIVES Previous findings regarding a possible association between beta-blocker use and depression are mixed. To our knowledge there have been no studies investigating the association of beta-blockers with depression in primary care hypertension patients without previous myocardial infarction. The aim of this study was to determine the relation between lipophilic beta-blocker ...

This issue of Resuscitation includes a review of beta-blocker treatment for cardiac arrest.1 At first, the very idea of administering a beta-blocker simultaneously with the recommended vasopressor might seem like driving your car with one foot on the brakes and the other on the gas pedal. How did we get here? There has been a great search for the optimal vasopressor to improve coronary and cere...

Recent evidence from randomized controlled trials has provided compelling evidence to support the use of beta blockers in most patients with heart failure due to systolic dysfunction. There is little disagreement about the mortality benefit provided by adding beta blockers to standard therapy, which may include angiotensin-converting enzyme inhibitors, diuretics, and sometimes digoxin. A few ar...

Published online 28 November 2001. Recent guidelines for hypertension management differ in their recommendations for routine firstline treatment for hypertension, as have previous generations of guidelines. For example, the United States JNC VI and British Hypertension Society guidelines both recommend low-dose diuretics and beta-blockers as first-line treatment unless there are compelling cont...

1930 www.thelancet.com Vol 372 December 6, 2008 or febuxostat). Enhanced understanding of pathophysiological mechanisms might lead to improved drugs, with reduced potential for side-eff ects compared with today’s uricosurics. Even more exciting is the idea that responding to the defects of these transporter proteins might have further benefi cial eff ects, because they could also transport othe...

AIMS Improved prognosis of patients with chronic systolic heart failure by treatment with beta-blockers has been shown in several randomized controlled multicentre trials. However, in clinical practice only a part of heart failure patients meet the inclusion criteria of these trials. The present study evaluates whether reduction of mortality by beta-blockers also can be achieved in patients pre...

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare potentially life-threatening genetic heart disease. Non-selective beta-blockers (BBs, namely nadolol and propranolol) are highly effective in reducing CPVT-triggered arrhythmic events. However, some patients suffer from unacceptable BB side effects might require BB-free treatment strategies that include flecainide, left card...

Antinuclear antibodies (ANA) were found in 54 (7.0%) out of 767 treated hypertensive patients compared with 59 (2.4%) out of 2470 healthy controls. Inclusion of a non-practolol beta-blocker in the treatment regimen did not significantly affect the incidence of ANA. ANA was found in significantly more patients being treated with methyldopa (13.0%) than patients receiving other hypotensive agents...

A controlled, double blind, crossover study was carried out to ascertain the effect of single doses of selective (100 mg atenolol) and non-selective (160 mg propranolol) beta blocker on pulmonary function and tracheobronchial mucociliary clearance. The study group comprised 12 healthy, young subjects. Adequate and comparable blockade was achieved with both drugs, the administration of which res...